首页> The Lancet. Haematology> Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Claire N,Harrison

第一单位： Guy's and St Thomas' NHS Foundation Trust, London, UK. Electronic address: claire.harrison@gstt.nhs.uk.

作者： Claire N,Harrison ^[1] ; Ruben,Mesa ^[2] ; Moshe,Talpaz ^[3] ; Haifa Kathrin,Al-Ali ^[4] ; Blanca,Xicoy ^[5] ; Francesco,Passamonti ^[6] ; Francesca,Palandri ^[7] ; Giulia,Benevolo ^[8] ; Alessandro Maria,Vannucchi ^[9] ; Clemence,Mediavilla ^[10] ; Alessandra,Iurlo ^[11] ; InHo,Kim ^[12] ; Shelonitda,Rose ^[13] ; Patrick,Brown ^[13] ; Christopher,Hernandez ^[13] ; Jia,Wang ^[13] ; Jean-Jacques,Kiladjian ^[14]

作者单位： Guy's and St Thomas' NHS Foundation Trust, London, UK. Electronic address: claire.harrison@gstt.nhs.uk. ^[1] Wake Forest University School of Medicine, Winston-Salem, NC, USA. ^[2] University of Michigan Cancer Center, Ann Arbor, MI, USA. ^[3] Universitätsklinikum Halle, Saale, Germany. ^[4] Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol-Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain. ^[5] Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy. ^[6] IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. ^[7] AOU Città de Salute e Scienza, Torino, Italy. ^[8] AOU Careggi, Universita di Firenze, Florence, Italy. ^[9] Hôpital Haut-Leveque, Bordeaux, France. ^[10] Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. ^[11] Seoul National University Hospital, Seoul, South Korea. ^[12] Bristol Myers Squibb, Princeton, NJ, USA. ^[13] Hospital Saint Louis and University Paris Cité, Paris, France. ^[14]

医学主题词人类(Humans);原发性骨髓纤维化(Primary Myelofibrosis);嘧啶类(Pyrimidines);腈类(Nitriles);吡唑类(Pyrazoles);男(雄)性(Male);女(雌)性(Female);老年人(Aged);中年人(Middle Aged);吡咯烷类(Pyrrolidines);磺胺类(Sulfonamides);治疗结果(Treatment Outcome);老年人, 80以上(Aged, 80 and over);成年人(Adult)

DOI 10.1016/S2352-3026(24)00212-6

PMID 39265613

发布时间 2025-07-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

The Lancet. Haematology

2024年11卷10期

e729-e740页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览1

点击下载本期目录封面

The Lancet. Haematology

2024年11卷10期

e729-e740页

检索历史清除

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.

The Lancet. Haematology

相似文献

同项目论文

The Lancet. Haematology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.

The Lancet. Haematology

相似文献

同项目论文

The Lancet. Haematology

相关期刊

检索历史清除